+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Melanocortin Receptor 4 - Pipeline Review, H2 2019

  • ID: 4900215
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 80 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aequus BioPharma Inc
  • Eton Pharmaceuticals Inc
  • Palatin Technologies Inc
  • MORE
Melanocortin Receptor 4 - Pipeline Review, H2 2019

Summary

Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report Melanocortin Receptor 4 - Pipeline Review, H2 2019, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Melanocortin Receptor 4 (MC4R) - Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 5 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Genetic Disorders, Musculoskeletal Disorders, Central Nervous System and Immunology which include indications Obesity, Type 2 Diabetes, Cachexia, Gouty Arthritis (Gout), Infantile Spasm (West Syndrome), Lipodystrophy (Lipoatrophy), Metabolic Syndrome, Multiple Sclerosis, Prader-Willi Syndrome (PWS), Rheumatoid Arthritis and Smith-Magenis Syndrome (Chromosome 17p11.2 Deletion Syndrome).

Furthermore, this report also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)
  • The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aequus BioPharma Inc
  • Eton Pharmaceuticals Inc
  • Palatin Technologies Inc
  • MORE
Introduction
Report Coverage
Melanocortin Receptor 4 (MC4R) - Overview
Melanocortin Receptor 4 (MC4R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development
Aequus BioPharma Inc
Eton Pharmaceuticals Inc
Palatin Technologies Inc
Rhythm Pharmaceuticals Inc
Melanocortin Receptor 4 (MC4R) - Drug Profiles
(liraglutide + setmelanotide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQB-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bremelanotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-8905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-9610 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setmelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setmelanotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize MC4-R for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melanocortin Receptor 4 (MC4R) - Dormant Products
Melanocortin Receptor 4 (MC4R) - Discontinued Products
Melanocortin Receptor 4 (MC4R) - Product Development Milestones
Featured News & Press Releases
Dec 16, 2019: First patient enrolled in Mallinckrodt phase 4 trial of Acthar Gel (Repository Corticotropin Injection) for Severe Keratitis
Dec 05, 2019: Rhythm Pharmaceuticals completes enrollment of pivotal cohort in phase 3 clinical trial evaluating Setmelanotide in Bardet-Biedl and Alstrom Syndromes
Nov 26, 2019: Data on Acthar Gel (Repository Corticotropin Injection) Therapy in Symptomatic Sarcoidosis published in Therapeutic Advances in Respiratory Disease
Nov 12, 2019: Mallinckrodt announces new clinical data evaluating Acthar Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting
Nov 07, 2019: Mallinckrodt announces data Publication on the treatment Effectiveness of Acthar Gel (Repository Corticotropin Injection) for resolution of multiple sclerosis relapse in a U.S. Health Plan Population
Nov 04, 2019: Rhythm Pharmaceuticals announces late-breaking data from phase 3 trials of Setmelanotide in POMC and LEPR deficiency obesities at ObesityWeek 2019
Oct 30, 2019: Rhythm Pharmaceuticals announces late-breaking data presentations at ObesityWeek 2019
Oct 16, 2019: Vyleesi phase 3 data to be presented at the 13th European Society Of Gynecology Congress
Oct 01, 2019: Mallinckrodt announces positive top-line findings from its observational registry assessing relapse recovery in multiple sclerosis relapse patients treated with Acthar Gel (Repository Corticotropin Injection)
Sep 25, 2019: Rhythm Pharmaceuticals provides update on research and development programs
Sep 13, 2019: Mallinckrodt analysis suggests Acthar Gel may be a cost-effective option compared to other late-line, adult treatments for Multiple Sclerosis Relapse
Sep 09, 2019: Rhythm Pharmaceuticals to provide an update on genetic sequencing efforts and expansion of Phase 2 Basket study with four additional rare MC4R Pathway-driven Disorders
Aug 27, 2019: AMAG Pharmaceuticals announces commercial availability of Vyleesi (Bremelanotide Injection)
Aug 07, 2019: Rhythm Pharmaceuticals announces positive topline results from pivotal phase 3 clinical trials evaluating Setmelanotide in POMC and LEPR deficiency obesities
Aug 06, 2019: Palatin Technologies to present data on Vyleesi at Canaccord Genuity's 39th Annual Growth Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Aequus BioPharma Inc, H2 2019
Pipeline by Eton Pharmaceuticals Inc, H2 2019
Pipeline by Palatin Technologies Inc, H2 2019
Pipeline by Rhythm Pharmaceuticals Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aequus BioPharma Inc
  • Eton Pharmaceuticals Inc
  • Palatin Technologies Inc
  • Rhythm Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll